News
(2)April 2026
Kyverna (KYTX) reports positive miv-cel results for Stiff Person Syndrome
# 📰 What This Document Is 🧬 This filing is an 8-K report—a mandatory filing used to announce material corporate events. It is structured as a press release detailing the incredible results of a major clinical trial. You should expect a deep dive into the science, the clinical data, and the company
Kyverna (KYTX) reports miv-cel achieves drug-free gMG remission lasting 52 weeks
# 📰 What This Document Is 🔬 This filing is an 8-K report and accompanying press release from Kyverna Therapeutics. It’s an announcement designed to share highly positive, long-term clinical data on their lead drug candidate, miv-cel. Generally, an 8-K is used to announce material, significant news
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.